Dissaneevate P, Warne G L
Department of Endocrinology and Diabetes, Royal Children's Hospital, Parkville, Victoria, Australia.
J Pediatr Endocrinol Metab. 1998 Jul-Aug;11(4):531-41. doi: 10.1515/jpem.1998.11.4.531.
Six adolescents, five males with prolactin-secreting pituitary macroadenomas and one female with idiopathic hyperprolactinaemia, are described. Their ages at presentation ranged from 13 years 7 months to 16 years 6 months. Presenting symptoms included headache, visual field defect, arrested growth and puberty. Only two cases had galactorrhoea. Every case had an elevated serum prolactin level. Three had surgery before the results of serum prolactin were to hand. Each patient was treated with bromocriptine. Bromocriptine suppressed serum prolactin level to normal in four cases, but in the girl with idiopathic hyperprolactinaemia, bromocriptine was not useful. In two boys, serum prolactin was not suppressed with bromocriptine therapy alone, and they were subsequently treated with cabergoline, surgery and irradiation. Nevertheless, in children and adolescents with prolactin-secreting pituitary adenoma, bromocriptine should be the first line of treatment.
本文描述了6名青少年患者,其中5名男性患有分泌催乳素的垂体大腺瘤,1名女性患有特发性高催乳素血症。他们就诊时的年龄在13岁7个月至16岁6个月之间。临床表现包括头痛、视野缺损、生长发育停滞和青春期发育迟缓。仅2例有溢乳症状。所有病例血清催乳素水平均升高。3例在血清催乳素结果出来之前就接受了手术。每位患者均接受了溴隐亭治疗。4例患者溴隐亭治疗后血清催乳素水平降至正常,但特发性高催乳素血症的女孩使用溴隐亭无效。2名男孩仅用溴隐亭治疗血清催乳素未得到抑制,随后他们接受了卡麦角林、手术和放疗。尽管如此,对于患有分泌催乳素的垂体腺瘤的儿童和青少年,溴隐亭仍应作为一线治疗药物。